

# Nikoletta Szabó<sup>3</sup>

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7974011/publications.pdf>

Version: 2024-02-01

37  
papers

857  
citations

516710

16  
h-index

501196

28  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Connectivity Lateralisation Shift of Resting State Networks is Linked to Visuospatial Memory and White Matter Microstructure in Relapsingâ€“Remitting Multiple Sclerosis. <i>Brain Topography</i> , 2022, 35, 268-275.	1.8	3
2	The effect of lesion location on visuospatial attentional bias in patients with multiple sclerosis.. <i>Neuropsychology</i> , 2022, 36, 150-158.	1.3	0
3	Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance. <i>Frontiers in Neurology</i> , 2021, 12, 619135.	2.4	4
4	Diffusion kurtosis imaging detects the timeâ€“dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 158, 779-797.	3.9	12
5	Resting-state functional heterogeneity of the right insula contributes to pain sensitivity. <i>Scientific Reports</i> , 2021, 11, 22945.	3.3	16
6	Temporal instability of salience network activity in migraine with aura. <i>Pain</i> , 2020, 161, 856-864.	4.2	23
7	Altered brain network function during attention-modulated visual processing in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852095836.	3.0	9
8	Brain MRI Diffusion Encoding Direction Number Affects Tractâ€“Based Spatial Statistics Results in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020, 30, 512-522.	2.0	5
9	Are Migraine With and Without Aura Really Different Entities?. <i>Frontiers in Neurology</i> , 2019, 10, 982.	2.4	24
10	Altered Resting State Functional Activity and Microstructure of the White Matter in Migraine With Aura. <i>Frontiers in Neurology</i> , 2019, 10, 1039.	2.4	17
11	Distinctive Patterns of Seizure-Related White Matter Alterations in Right and Left Temporal Lobe Epilepsy. <i>Frontiers in Neurology</i> , 2019, 10, 986.	2.4	6
12	Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinsonâ€™s Disease. <i>Neurotoxicity Research</i> , 2019, 36, 724-735.	2.7	12
13	Gray Matter Atrophy to Explain Subclinical Oculomotor Deficit in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 589.	2.4	3
14	Lateralisation of the white matter microstructure associated with the hemispheric spatial attention dominance. <i>PLoS ONE</i> , 2019, 14, e0216032.	2.5	2
15	Principles of diffusion kurtosis imaging and its role in early diagnosis of neurodegenerative disorders. <i>Brain Research Bulletin</i> , 2018, 139, 91-98.	3.0	72
16	Macro- and microstructural alterations of the subcortical structures in episodic cluster headache. <i>Cephalalgia</i> , 2018, 38, 662-673.	3.9	18
17	Correlation of neurochemical and imaging markers in migraine. <i>Neurology</i> , 2018, 91, e1166-e1174.	1.1	9
18	White matter alterations in Parkinsonâ€™s disease with normal cognition precede grey matter atrophy. <i>PLoS ONE</i> , 2018, 13, e0187939.	2.5	57

#	ARTICLE	IF	CITATIONS
19	The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 1172.	2.4	23
20	Interictal brain activity differs in migraine with and without aura: resting state fMRI study. <i>Journal of Headache and Pain</i> , 2017, 18, 8.	6.0	56
21	Early and progressive microstructural brain changes in mice overexpressing human $\alpha$ -Synuclein detected by diffusion kurtosis imaging. <i>Brain, Behavior, and Immunity</i> , 2017, 61, 197-208.	4.1	28
22	Ipsilateral Alteration of Resting State Activity Suggests That Cortical Dysfunction Contributes to the Pathogenesis of Cluster Headache. <i>Brain Topography</i> , 2017, 30, 281-289.	1.8	16
23	A New Division of Schizophrenia Revealed Expanded Bilateral Brain Structural Abnormalities of the Association Cortices. <i>Frontiers in Psychiatry</i> , 2017, 8, 127.	2.6	5
24	Evidence for Plastic Processes in Migraine with Aura: A Diffusion Weighted MRI Study. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 138.	1.7	39
25	Release of PACAP-38 in episodic cluster headache patients – an exploratory study. <i>Journal of Headache and Pain</i> , 2016, 17, 69.	6.0	79
26	Late-stage $\alpha$ -synuclein accumulation in TNWT61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging. <i>Journal of Neurochemistry</i> , 2016, 136, 1259-1269.	3.9	18
27	Male brain ages faster: the age and gender dependence of subcortical volumes. <i>Brain Imaging and Behavior</i> , 2016, 10, 901-910.	2.1	54
28	Difference in white matter microstructure in differential diagnosis of normal pressure hydrocephalus and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2016, 140, 52-59.	1.4	16
29	GRAY MATTER ATROPHY IN PRESYMPTOMATIC HUNTINGTON'S PATIENTS. <i>Ideggyogyaszati Szemle</i> , 2016, 69, 261-267.	0.7	1
30	Audio-visual integration through the parallel visual pathways. <i>Brain Research</i> , 2015, 1624, 71-77.	2.2	10
31	Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of $\alpha$ -Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study. <i>Neurotoxicity Research</i> , 2015, 28, 281-289.	2.7	17
32	An investigation of the white matter microstructure in motion detection using diffusion MRI. <i>Brain Research</i> , 2014, 1570, 35-42.	2.2	7
33	White matter disintegration in cluster headache. <i>Journal of Headache and Pain</i> , 2013, 14, 64.	6.0	26
34	Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington's disease. <i>Ideggyogyaszati Szemle</i> , 2013, 66, 399-405.	0.7	4
35	White matter microstructural alterations in migraine: A diffusion-weighted MRI study. <i>Pain</i> , 2012, 153, 651-656.	4.2	81
36	Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach. <i>Journal of the Neurological Sciences</i> , 2011, 310, 256-260.	0.6	61

#	ARTICLE	IF	CITATIONS
37	Novel therapy in Parkinson's disease: adenosine A <sub>2A</sub> receptor antagonists. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 441-455.	3.3	24